Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$38.28 USD
+0.13 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.24 -0.04 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RYTM 38.28 +0.13(0.34%)
Will RYTM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
Other News for RYTM
Analyst Expectations For Rhythm Pharmaceuticals's Future
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Commit To Purchase Rhythm Pharmaceuticals At $25, Earn 8.6% Annualized Using Options
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson